Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies

BACKGROUND: We hypothesized that the addition of receptor tyrosine kinase inhibitors (RTKis, e.g., lapatinib, erlotinib, cetuximab, bevacizumab, panitumumab) to radiotherapy-based treatment for solid tumors does not increase overall survival but may increase toxicity. METHODS: Population, Interventi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tchelebi, Leila T, Batchelder, Emma, Wang, Ming, Lehrer, Eric J, Drabick, Joseph J, Sharma, Navesh, Machtay, Mitchell, Trifiletti, Daniel M, Zaorsky, Nicholas G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328097/
https://www.ncbi.nlm.nih.gov/pubmed/34350378
http://dx.doi.org/10.1093/jncics/pkab050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328097/
https://www.ncbi.nlm.nih.gov/pubmed/34350378
http://dx.doi.org/10.1093/jncics/pkab050

Ejemplares similares